tirzepatide 2.5 mg/0.5 ml pnij Lilly releases Zepbound® (tirzepatide) single-dose vials, expanding supply and access for adults living with obesity Lilly launches lower-price weight-loss drug

Eli Lilly, the maker of Zepbound and Mounjaro, is also taking a firm stance

That means Eli Lilly will likely face more lawsuits from people who were harmed by Mounjaro

Well continue to track all of our patients with surveys and follow up appointments to get the most complete picture of weight loss, but the initial results are very exciting

Our research found it affected 5.4% of semaglutide users and 9.6% of tirzepatide users at 12 months

Reasons Why Some People Hit a Plateau in Their Weight Loss Journey Several reasons can contribute to hitting a weight loss plateau

Our team helps clients assess risk and make informed decisions grounded in current law and enforcement trends